Redmile Group LLC lifted its stake in ALX Oncology Holdings Inc. (NASDAQ:ALXO – Free Report) by 143.9% in the first quarter, HoldingsChannel.com reports. The firm owned 7,964,188 shares of the company’s stock after purchasing an additional 4,699,470 shares during the quarter. ALX Oncology comprises 1.1% of Redmile Group LLC’s investment portfolio, making the stock its 15th largest position. Redmile Group LLC owned 0.06% of ALX Oncology worth $15,968,000 at the end of the most recent quarter.
Other institutional investors have also recently bought and sold shares of the company. venBio Partners LLC boosted its position in ALX Oncology by 32.8% in the 1st quarter. venBio Partners LLC now owns 12,884,638 shares of the company’s stock valued at $25,834,000 after buying an additional 3,184,713 shares during the last quarter. Orbimed Advisors LLC acquired a new stake in shares of ALX Oncology in the 1st quarter valued at $5,747,000. Ameriprise Financial Inc. bought a new stake in shares of ALX Oncology during the third quarter worth $1,195,000. Renaissance Technologies LLC raised its position in shares of ALX Oncology by 73.2% during the first quarter. Renaissance Technologies LLC now owns 732,599 shares of the company’s stock worth $1,469,000 after acquiring an additional 309,500 shares during the last quarter. Finally, Jane Street Group LLC acquired a new position in shares of ALX Oncology during the second quarter valued at $84,000. Institutional investors own 97.97% of the company’s stock.
ALX Oncology Price Performance
ALXO opened at $1.99 on Wednesday. The company has a fifty day moving average price of $1.88 and a two-hundred day moving average price of $1.90. The firm has a market capitalization of $267.77 million, a PE ratio of -1.34 and a beta of 0.42. ALX Oncology Holdings Inc. has a 52 week low of $0.51 and a 52 week high of $2.66. The company has a debt-to-equity ratio of 0.02, a quick ratio of 7.21 and a current ratio of 7.21.
Analyst Ratings Changes
Several equities analysts recently issued reports on ALXO shares. Wall Street Zen upgraded ALX Oncology from a “sell” rating to a “hold” rating in a report on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of ALX Oncology in a research report on Friday, June 26th. Five analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $4.60.
Read Our Latest Stock Report on ALX Oncology
ALX Oncology Company Profile
ALX Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Redwood City, California, focused on developing next-generation immuno-oncology therapies. The company’s mission is to harness and amplify both innate and adaptive immune responses to improve outcomes for patients with a range of solid tumors and hematologic malignancies.
The lead candidate in ALX Oncology’s pipeline is evorpacept (ALX148), a high-affinity CD47-blocking Fc-silenced fusion protein designed to enhance macrophage-mediated phagocytosis of cancer cells when combined with standard therapeutic antibodies or immune checkpoint inhibitors.
Read More
- Five stocks we like better than ALX Oncology
- These 3 Stocks Have Soared in 2026—Can They Keep Climbing?
- Hasbro’s Earnings Beat Shows Why This Is No Longer Just a Toy Story
- Rambus: Another AI Phoenix Ready to Rise From the Ashes of Correction
- Chips & Clips: Memory Tariffs Rewire Tech Supply Chains
Want to see what other hedge funds are holding ALXO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ALX Oncology Holdings Inc. (NASDAQ:ALXO – Free Report).
Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.
